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reimbursement methods, HTAs at the national level are more common.
CONCLUSIONS: Basic drivers of market access, such as health care spend, financ-
ing structure and regulatory policy create both independent and interdependent
mechanisms that support access to new device technologies. Consideration of
country level conditions and hurdles will inform device manufacturers’ differential
strategies to enter established and emerging markets.
PHP196
STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT (HTA)
OF NOVEL MEDICAL DEVICES
Hidefjall P
KTH Royal School of Technology, Huddinge, Huddinge, Sweden
HTA for medical devices follows the path of drugs in many countries. There are
however substantial differences that should be considered when evaluating med-
ical devices. Drummond (2009) describes six important differences. Medical de-
vices: 1) are often diagnostic therefore requiring to consider their related therapeu-
tic effects; 2) have faster product cycles often making trial results outdated; 3)
performance depend on users’ skills and complementary investments in training
and equipment; 4) innovation may cause a shift from one in-patient setting (oper-
ating room) to another (cathlab) or to an out-patient setting with substantial cost-
effects; 5) are manufacturer specific, making it difficult to draw conclusions about
product class effects; 6) innovation may be difficult to protect with patents thus
encouraging imitation with resulting falling prices. In addition to issues 1-6, regu-
latory approval of a device does not require the same level of evidence as for drugs.
Despite initial poor evidence, decisions on health care resource-use based on cost-
utility (QALY) need to be made throughout the product lifecycle. This can be
achieved by involving stakeholders in regular, timely data exchange for model
updating, considering issues 1-6 above. As medical devices directly affect several
stakeholders, their respective treatment costs from accounting systems can be
used (4). As product registries are continuously updated the improving perfor-
mance due to new devices and user learning is reflected (2-3). According to regu-
latory requirements manufacturers must evaluate their product performance and
notify competent authorities of adverse events. Such data should update cost-
utility evaluations relating to manufacturer specific patient morbidity (5). Further-
more as outcomes data are increasingly captured by devices directly or apps and
electronically transferred to electronic health records, the burden on manufactur-
ers to administrate registries may be lessened (2). As medical devices are regularly
procured in tenders, their product prices should be used (6). In turn HTA outcomes
should inform tenders.
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OBJECTIVE AND UNBIASED INDICATORS OF ENVIRONMENTAL AND SOCIETAL
IMPACTS
Wright AJ, Froehlich HJ
PHMR Associates, London, UK
OBJECTIVE: To establish the extent to which existing sustainability indices provide
pertinent and transparent evidence of the environmental and social impacts of
health technology providers. METHOD: A search was undertaken to identify a
comprehensive list of sustainability indices for study. For each of these the follow-
ing criteria were identified; target constituency, specific environmental or social
domains being measured, criteria for inclusion, data sources and ranking or scor-
ing methodology. RESULTS: The majority of indices were found to be focused on
the needs of investors rather than purchasers. The indices either measured specific
environmental or social domains such as carbon efficiency, water risks and social
impacts, or provided a broader measure of sustainability by combining environ-
mental, social and governance issues together in a single metric. Incorporation
within an index often required inclusion in pre-existing non sustainability criteria
against which additional sustainability measures were applied. Data used within
the indexes reviewed were found to have been derived from publically available
sources such as websites and company reports, or from data submitted by the
organisations under evaluation to rating research groups. Few of the indices pub-
lished a level of methodological transparency that could provide sufficient visibil-
ity in order to understand how they are derived. CONCLUSION: There remains a
latent need among purchasers for a verifiable method of measuring sustainability
of providers. In order for a sustainability index to provide utility in the comparison
of health technology providers the following criteria must be met; The index
should be open to all Health Technology providers, methods used by the index to
measure performance should be transparent. None of the current sustainability
indexes reviewed fulfilled these criteria. Further study is needed to identify the
environmental and social domains of importance to purchasers and the best ap-
proach for deriving this data.
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Research suggests that routine collection of Patient Reported Outcome Measures
(PROMs) can contribute to clinical decision-making and improve health, but their
systematic implementation in Ontario, outside the Edmonton Symptom Assess-
ment (ESAS), has not yet occurred. While ESAS is a valid symptom screening tool, it
does not allow customization to disease specific symptoms or toxicities nor does it
reflect the multidimensional impact of cancer on physical, emotional and social
health. Reaching consensus on a core set of PROMS for each of these domains is
critical to improving health and monitoring the impact of cancer. However, apply-
ing numerous PROMs is burdensome to patients and evaluators. We are now mov-
ing forward to make routine PROM data collection a reality in the cancer system.
On-PROST aims to improve the patient experience of cancer and the quality of care
through the routine collection of a standardized set of (PROMs) for use in clinical
care, and to advance the science of cancer treatment through research across the
cancer continuum. Based on initial consensus for the implementation of core
PROM data (PROMs-Cancer Core), we will develop a cohesive research agenda and
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations for research use and clinical practice. On-Prost
focuses on five cancer research areas: Health Services Research; Biomarker Re-
search; Radiation Oncology; Palliative and Supportive Care; and the PROMs-Cancer
Core items. We plan to develop national and international partnerships, and to
foster the development, standardization and implementation of core PROMs rele-
vant across cancer populations and for disease specific purposes for routine clinical
care and trials. Our goal is to foster common PROMs with multiple purposes, in-
cluding performance and impact of cancer reporting, that will help deliver person-
alized quality care and treatment, and will concretely impact on cancer control and
policy over the next five years.
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YEARS AFTER THE INTRODUCTION OF THE AMNOG
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With the introduction of the German Pharmaceutical Market Reorganisation Act
(German: “Arzneimittelmarktneuordnungsgesetz” (AMNOG)) in January 2011,
pharmaceutical entrepreneurs have to present a dossier to demonstrate the addi-
tional benefit of a new pharmaceutical at product launch in the German market.
Pharmaceuticals failing to demonstrate additional benefit against the standard of
care in the corresponding indication can be included in an existing reference price
group or even trigger the building of a new one. Top-selling reference price markets
with many newcomers or price-aggressive competitors are at risk of a repeated
examination through the federal joint committee (G-BA) in short intervals, result-
ing in a frequent updating of the reference price. This triggers a cascade, the so
called “Kellertreppeneffekt” (Race to the Bottom), which could result in a rapidly
decreasing reference price. One parameter of interest to assure an adequate secu-
rity of supply is the measure value 160, assuring that at least 20% of packages and
20% of prescriptions are available at a lower price than the new reference price. To
avoid the cascade, alternative, lower measure values, such as the measure value
100, can be applied. The measure value 100 is feasible for reference price groups
with a large amount of products which are free of patients’ copayment. Pharma-
ceuticals are normally free of patients’ copayment if the product price is 30% lower
than the corresponding reference price. The focus of our presentation is to analyze
the impact of the AMNOG on 10 top-seller reference price groups and to evaluate
further adjustments to the reference price level of these groups through varying
measure values. Furthermore, additional parameters of interest influencing the
reference price level will be considered.
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Health literacy (HL) research has mainly focused on the skills and abilities of indi-
viduals in the health care setting. For the past 20 years, most research has been
conducted in North America. However, HL is now gaining political support at Eu-
ropean Union level. This presentation is concerned with attitudes that nationally
representative survey respondents in Ireland have towards improving their health
by seeking a more health literate health care system. Two waves of the Survey of
Lifestyle, Attitudes and Nutrition (SLAN 1998 & 2002) were used in this analysis.
The primary focus of this study was to look across the socioeconomic gradient and
see whether Irish health policymakers should invest in HL as a health inequalities
or a public health issue. A secondary objective was to look at preventive health care
utilization (General health check-up, blood pressure check-up, blood cholesterol
check-up) using the HL variable as the main independent variable stratified by
gender and medical card eligibility.
The constructive dependent variable (termed ‘effective demand for a health liter-
ate health care system’) showed that 46% of respondents desired at least one at-
tribute on a health literate health care system. Various multivariate logistic regres-
sion models used social class grouping, medical card eligibility, level of education
and employment status as the main socioeconomic gradient variables. No discern-
ible trend emerged among the socioeconomic variables. This suggests that HL
should be viewed as a public health issue with a policy focus at a system level.
Consistently, females (OR 1.15; 95%:1.04 -1.28) were more likely than males to seek a
health literate health care system. However, males without a medical card with an effec-
tive demand for health literate health care system were more likely to get a general
check-up (OR 1.23; 95%:1.03 -1.47). The investment in making the system more user-
friendly would benefit all in society and not those stigmatized as having low literacy.
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CAN RISK MANAGEMENT PLANS (RMP) CONTRIBUTE TO HEALTH TECHNOLOGY
ASSESSMENT (HTA) AND KNOWLEDGE OF SAFETY IN EVERYDAY MEDICAL
PRACTICE?
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